CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Silk Biomaterials is developing a device called SilkByPass for regenerating small blood vessels using silk-based nanotechnology. This innovation aims to provide a safer and more effective alternative to traditional grafts used in coronary artery bypass surgeries.
Silk Biomaterials is a nanotechnology platform company.
Its goal is to revolutionize the €85bn global tissue engineering market by leveraging the biomimetic properties and the mechanical advantages of silk.
SilkByPass, a device designed for the regeneration of small blood vessels, will be the first product developed by Silk Biomaterials.
About 560k/year coronary artery bypass graft surgeries (CABG) are performed in OECD countries.
The current golden standard for CABG is autograft (mainly sapheno…
KLISBIO SRL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
